110 related articles for article (PubMed ID: 34182611)
21. Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers.
Hijazi Y; Welker H; Dorr AE; Tang JP; Blain R; Renzetti LM; Abbas R
J Clin Pharmacol; 2004 Dec; 44(12):1368-78. PubMed ID: 15545307
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.
Cass LM; Efthymiopoulos C; Bye A
Clin Pharmacokinet; 1999; 36 Suppl 1():1-11. PubMed ID: 10429835
[TBL] [Abstract][Full Text] [Related]
23. A First-in-Human Safety, Tolerability, and Pharmacokinetics Study of Benapenem in Healthy Chinese Volunteers.
Zhao CY; Lv Y; Zhu Y; Wei MJ; Liu MY; Ji XW; Kang ZS; Xia YH; Tian JH; Ma Y; Liu Y
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617093
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA).
Bjermer L; Kuna P; Jorup C; Bengtsson T; Rosenborg J
Drug Des Devel Ther; 2015; 9():753-62. PubMed ID: 25709399
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants.
Humeniuk R; Juneja K; Chen S; Ellis S; Anoshchenko O; Xiao D; Share A; Johnston M; Davies S; DeZure A; Llewellyn J; Osinusi A; Winter H; Girish S; Palaparthy R; Dresser M
Clin Transl Sci; 2023 Nov; 16(11):2276-2288. PubMed ID: 37688349
[TBL] [Abstract][Full Text] [Related]
26. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers.
Kankam MK; Burns JM; Collett MS; Corrado ML; Hincks JR
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0102921. PubMed ID: 34370575
[TBL] [Abstract][Full Text] [Related]
27. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
Jani RH; Kansagra K; Jain MR; Patel H
Clin Drug Investig; 2013 Nov; 33(11):809-16. PubMed ID: 24062180
[TBL] [Abstract][Full Text] [Related]
29. Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteers.
Zhu R; Chen H; Galanter J; She G; Cai F; Durk MR; Zou Y; Chen L; Kenny JR; Vadhavkar S; Warren S; Taylor G; Hwang O; Eliahu A; Wynne C; Owen R
Clin Transl Sci; 2022 May; 15(5):1225-1237. PubMed ID: 35157370
[TBL] [Abstract][Full Text] [Related]
30. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.
Ortiz S; Flach S; Caracta C; Gil EG; Jansat JM
J Clin Pharmacol; 2012 Jun; 52(6):819-27. PubMed ID: 21628603
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
[TBL] [Abstract][Full Text] [Related]
32. Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371.
Cho YS; Lim HS; Han S; Yoon SK; Kim H; Cho YL; Nam HS; Bae KS
Clin Ther; 2019 Jan; 41(1):92-106. PubMed ID: 30559004
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
[TBL] [Abstract][Full Text] [Related]
34. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
35. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
[TBL] [Abstract][Full Text] [Related]
36. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
van der Aar E; Desrivot J; Dupont S; Heckmann B; Fieuw A; Stutvoet S; Fagard L; Van de Wal K; Helmer E
J Clin Pharmacol; 2019 Oct; 59(10):1366-1378. PubMed ID: 31012984
[TBL] [Abstract][Full Text] [Related]
37. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
Zhou J; Limsakun T; Yin O; Warren V; Zamora C; Atiee G; Kochan J; Pav J; Kobayashi F; Vashi V; Dishy V
J Clin Pharmacol; 2019 Dec; 59(12):1669-1677. PubMed ID: 31243790
[TBL] [Abstract][Full Text] [Related]
38. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
40. A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants.
Feng S; Gane E; Schwabe C; Zhu M; Triyatni M; Zhou J; Bo Q; Jin Y
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
